{"id":1938,"date":"2024-04-03T15:53:10","date_gmt":"2024-04-03T15:53:10","guid":{"rendered":"https:\/\/stoxpo.com\/?p=1938"},"modified":"2024-04-03T15:53:11","modified_gmt":"2024-04-03T15:53:11","slug":"fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/","title":{"rendered":"Fanapt Receives FDA Approval for Bipolar I Disorder Treatment"},"content":{"rendered":"\n

Vanda Pharmaceuticals Expands Fanapt Franchise with Novel Indication<\/h3>\n\n\n\n

Vanda Pharmaceuticals (VNDA) has announced a significant milestone as the U.S. Food and Drug Administration (FDA) approves Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This approval marks a substantial expansion of Fanapt’s utility beyond its previous use in schizophrenia treatment since 2009.<\/p>\n\n\n\n

Bipolar disorder affects approximately 2.8% of the U.S. adult population, with severe cases impacting 83%. With Fanapt now approved for bipolar I disorder, patients and healthcare providers gain a new treatment option backed by over 100,000 patient years of experience. The approval underscores Vanda’s commitment to addressing high unmet medical needs and improving patient outcomes.<\/p>\n\n\n\n

Dr. Mihael H. Polymeropoulos, Vanda’s President, CEO, and Chairman of the Board, emphasized the complexity of manic or mixed episodes associated with bipolar I disorder and the need for trusted treatment options tailored to individual patient needs. The approval of Fanapt represents a pivotal advancement in managing bipolar disorder and reflects Vanda’s dedication to innovation and patient-centric care.<\/p>\n\n\n\n

Read original press release:here<\/mark><\/a><\/p>\n\n\n\n

You might like this article:Amazon\u2019s AWS Division Implements Layoffs Amidst Shifting Market Dynamics<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Vanda Pharmaceuticals Expands Fanapt Franchise with Novel Indication Vanda Pharmaceuticals (VNDA) has announced a significant milestone as the U.S. Food and Drug Administration (FDA) approves Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This approval marks a substantial expansion of Fanapt’s utility beyond its […]<\/p>\n","protected":false},"author":1,"featured_media":1430,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[309,359],"tags":[],"coauthors":[453],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1938"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1938"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1938\/revisions"}],"predecessor-version":[{"id":1939,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1938\/revisions\/1939"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1430"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=1938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=1938"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=1938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}